Author: Alkeus Pharmaceuticals

Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease

June 8, 2026
Alkeus Pharmaceuticals Announces Presentation of Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting

May 24, 2026

Alkeus Pharmaceuticals Announces First Patient Dosed in Pivotal Global Phase 3 NORTHSTAR Study of Oral Gildeuretinol in Stargardt Disease